On-target, on-time modulation of bone resorption to fight against fracture

Patrizia D’Amelio, MD, PhD
E-mail: patrizia.damelio@novaicos.com
Novaicos Team
Multidisciplinar team with scientific and technical experience and skills in nanomaterial and immunology.

Luca Gigliotti PhD, CEO/CSO.
lab coordinator, responsible for biomaterials.

Prof. Umberto DIANZANI, MD, PhD. R&D supervisor, Communication manager

Elena BOGGIO, PhD, CTO.
Lab coordinator

Patrizia D'AMELIO, MD, PhD
Clinical Area Manager

Maurizio Michele ZUZZARO
Financial Strategist
ICOS/ICOSL endogenous pathway

- Discovered by Prof. U. Dianzani in 1996
- Mediates T cell/APC interaction
ICOS/ICOSL in bone turnover

This information is current as of March 3, 2017.

ICOS-Ligand Triggers Impaired Osteoclast Differentiation and Function In Vitro and In Vivo

Casiniro L, Gigliotti, Elena Boggio, Nausicaa Clemente, Yogesh Shivakumar, Erika Toth, Daniele Siblattero, Patrizia D’Amelio, Giovanni C. Issia, Chiari Dianzani, Junji Yagi, Jose M. Rojo, Annalisa Chocchetti, Renzo Boldrini, Michela Bosetti and Umberto Dianzani

J Immunol 2016; 197:3905-3916; Prepublished online 19 October 2016; doi: 10.4049/jimmunol.1600424
http://www.jimmunol.org/content/197/10/3905

NOVAICOS
Better life at any age
The innovative solution
«On-target, on-time control of bone erosion»

ICOS-Fc

Resorbing osteoclasts

Inactive osteoclasts

Osteoblasts

On-target:
- selective inhibits resorbing osteoclasts

On-time:
- quick wash out (20 days)
- allows bone remodelling

NOVAICOS
Better life at any age
ICOS-Fc activity in osteoporosis

Chronic model of osteoporosis

Acute model of osteoporosis

Untreated

Treated

NOVAICOS
Better life at any age
The number of osteoporosis: a hidden disease
Socio-economic cost

SOCIOECONOMIC BURDEN:
- Inhospital stay
- Rehabilitation costs
- Loss of independence
- Caregiver burden
- Increased mortality

EUROPE
31.7 BILLIONS

Direct costs of osteoporotic fractures

NOVAICOS
Better life at any age
GLOBAL MARKET FOR OSTEOPOROSIS DRUGS

8.8 BILLIONS $
Why NOVAICOS?

01 Innovative molecule
02 Solid preclinical data
03 Competitive advantage
04 Strong team
05 Huge social impact
06 Unmet medical needs
Patrizia D’Amelio, MD, PhD
E-mail: patrizia.damelio@novaicos.com
www.novaicos.com